Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Novo Nordisk Stock Skids After FDA Inspection Turns Up Problematic Bacteria In Key Plant

Novo Nordisk found "objectionable" bacteria in several batches of semaglutide, according to an FDA report. Novo Nordisk stock fell Thursday.

Investors Business Daily

Novo Nordisk Dives After FDA Reportedly Finds 'Objectionable' Conditions At A Key Wegovy Plant

Novo Nordisk stock skidded Monday on reports an inspection turned up "objectionable conditions" at a diabetes and weight-loss drugs manufacturing plant.

Investors Business Daily

Novo Nordisk beats LVMH to become Europe’s most valuable company after it takes its ‘miracle’ weight loss drug Wegovy to the U.K.

The Danish pharma giant overtook French luxury conglomerate LVMH as the most valuable European company, which held the title since 2021.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment

Novo Nordisk said Friday its obesity treatment, Wegovy, reduced heart-failure symptoms. But Novo Nordisk stock remained flat.

Investors Business Daily

Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo

Prescriptions of weight-loss and diabetes drugs have rocketed this year, giving Novo Nordisk stock and Eli Lilly stock more room to run.

Investors Business Daily

Novo Reverses Obesity-Related Winning Streak, Diving On Light Sales

Novo is restricting some doses of Wegovy in the U.S., the company said Thursday. Novo Nordisk stock fell on light second-quarter sales.

Investors Business Daily

Eli Lilly Stock Has Tumbled 22% Since Its August High. Is It A Buy Or A Sell?

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell today?

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why The Weight-Loss Bonanza Catapulted Lilly And Novo, But Hammered Dexcom And Others

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Investors Business Daily

Novo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Fortune

AI Stocks Lead These 5 Names Near Buy Points

Artificial intelligence stocks including chipmaker Marvell Technology (MRVL), Arista Networks (ANET) and Synopsys (SNPS), which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points. In addition to MRVL, ANET and SNPS stock, weight-loss drug leader Novo Nordisk (NVO) and Heico (HEI), a military…

Investors Business Daily

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

Investors Business Daily

Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Ozempic maker now wants to keep people from becoming obese in the first place

Novo Nordisk is investing in obesity prevention, the 'real big frontier' of weight loss.

The Street

Diet Drug Manufacturer Sues Alleged Knockoff US Competitors

Custom-made versions of Ozempic are hitting the weight loss and that could be thinning out Novo Nordisk's profits.

Investors Business Daily

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Barchart

Why You Should Go Overweight On Novo Nordisk Stock

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,

Investors Business Daily

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

An oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped.

Businessweek

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook

Novo Nordisk stock forged a new high Thursday after raising financial estimates, citing its diabetes and obesity treatments.

Investors Business Daily

Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $2.7 Billion Deal

Novo Nordisk stock popped Wednesday after the drugmaker inked a $2.7 billion deal that bolsters its diabetes and obesity treatments.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations